AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24627256 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 120
Study 24627256 — intervention group
Group type: COMPARATOR
Intervention: Traditional feeding
Number of subjects: 120
Study 23859673 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg IV qd followed by 400 mg PO qd
Number of subjects: 116
Study 23859673 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam 1.5 g IV qid followed by 750 mg PO q12h
Number of subjects: 116
Study 23859673 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 116
Study 23859673 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam
Number of subjects: 116
Study 23859673 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam therapy
Number of subjects: 116
Study 23859673 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to ED presentation >24 h
Number of subjects: 116
Study 20572416 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional device (PD)
Number of subjects: 38
Study 20572416 — intervention group
Group type: COMPARATOR
Intervention: CPAP (10 ± 3 cm H2O)
Number of subjects: 38
Study 18783303 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 1987
Study 18783303 — intervention group
Group type: COMPARATOR
Intervention: FU+LV
Number of subjects: 1987
Study 16600508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg)
Number of subjects: 24
Study 16600508 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (30 mg)
Number of subjects: 24
Study 16600508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14596361 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 40
Study 14596361 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg + Hydrochlorothiazide 12.5 mg
Number of subjects: 40
Study 10976273 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Number of subjects: 41
Study 10976273 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (Taxol)
Number of subjects: 41
Study 8971294 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g sucralfate
Number of subjects: 40
Study 8971294 — intervention group
Group type: COMPARATOR
Intervention: 100 mg hydrocortisone
Number of subjects: 40
Study 30168581 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Clinical Placement (SCP) - 40 hours
Number of subjects: 570
Study 30168581 — intervention group
Group type: COMPARATOR
Intervention: Traditional Clinical Placement (TCP) - 40 hours
Number of subjects: 570
Study 27040041 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg every 8 hours for 2 months)
Number of subjects: 50
Study 27040041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study 25400056 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic antimicrobial therapy with Fufanghuangbai liquid wet dressing and semiconductor laser irradiation (20 min twice daily for 7 days)
Number of subjects: 42
Study 25400056 — intervention group
Group type: COMPARATOR
Intervention: Control group with Fufanghuangbai liquid for external application
Number of subjects: 42
Study 23715447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentous injections with 4% articaine with epinephrine
Number of subjects: 36
Study 20925920 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training (150 mins/week at 60%-70% VO₂peak for 16 weeks)
Number of subjects: 174
Study 20925920 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high-intensity aerobic training (150 mins/week at 60%-100% VO₂peak for 16 weeks)
Number of subjects: 174
Study 20925920 — intervention group
Group type: COMPARATOR
Intervention: Attention control (progressive stretching for 16 weeks)
Number of subjects: 174
Study 18622840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed rigid dressing (ORD)
Number of subjects: 27
Study 18622840 — intervention group
Group type: COMPARATOR
Intervention: Conventional rigid dressing (C)
Number of subjects: 27
Study 18622840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 16324243 — intervention group
Group type: EXPERIMENTAL
Intervention: Stark cesarean section (Group A)
Number of subjects: 353
Study 16324243 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal incision cesarean section (Group B)
Number of subjects: 353
Study 16324243 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel incision cesarean section (Group C)
Number of subjects: 353
Study 11887942 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologists' readings using image features from CT and MR imaging
Number of subjects: 146
Study 11887942 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical prediction rules (SPRs) using features from all modalities
Number of subjects: 146
Study 11887942 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced MR imaging and contrast-enhanced CT
Number of subjects: 146
Study 10407840 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational training and cognitive psychotherapy for patients and counseling for their key persons
Number of subjects: 191
Study 7743788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 7743788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day
Number of subjects: 431
Study 7743788 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 431
Study 7743788 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of poor run-in adherers
Number of subjects: 431
Study 2160781 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Burst Stimulation (DBS) at 50 mA
Number of subjects: 21
Study 2160781 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Burst Stimulation (DBS) at 30 mA
Number of subjects: 21
Study 2160781 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Burst Stimulation (DBS) at 20 mA
Number of subjects: 21
Study 2160781 — intervention group
Group type: COMPARATOR
Intervention: Train-of-Four (TOF) at 50 mA
Number of subjects: 21
Study 2160781 — intervention group
Group type: COMPARATOR
Intervention: Train-of-Four (TOF) at 30 mA
Number of subjects: 21
Study 2160781 — intervention group
Group type: COMPARATOR
Intervention: Train-of-Four (TOF) at 20 mA
Number of subjects: 21
Study 7026344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day (short-term)
Number of subjects: 200
Study 7026344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 75 mg/day (short-term)
Number of subjects: 200
Study 7026344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (short-term)
Number of subjects: 200
Study 7026344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime (long-term)
Number of subjects: 200
Study 7026344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 30 mg at bedtime (long-term)
Number of subjects: 200
Study 7026344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (long-term)
Number of subjects: 200
Study 30580530 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 70
Study 30580530 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (control)
Number of subjects: 70
Study 27941358 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 66
Study 27941358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 26553006 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterols and inulin-enriched soymilk (2 g/day of phytosterols and 10 g/day of inulin)
Number of subjects: 240
Study 26553006 — intervention group
Group type: COMPARATOR
Intervention: Standard soymilk (control)
Number of subjects: 240
Study 23428186 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A injections
Number of subjects: 73
Study 23428186 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 73
Study 21875640 — intervention group
Group type: EXPERIMENTAL
Intervention: POs-Ca chewing gum
Number of subjects: 36
Study 21875640 — intervention group
Group type: EXPERIMENTAL
Intervention: POs-Ca+F chewing gum
Number of subjects: 36
Study 21875640 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 36
Study 19688627 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) 25 g daily for 14 days
Number of subjects: 14
Study 19688627 — intervention group
Group type: COMPARATOR
Intervention: Wheat Bran (WB) 25 g daily for 14 days
Number of subjects: 14
Study 17656071 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccade task performance in UHR patients
Number of subjects: 35
Study 17656071 — intervention group
Group type: COMPARATOR
Intervention: Antisaccade task performance in recent-onset schizophrenia patients
Number of subjects: 35
Study 17656071 — intervention group
Group type: COMPARATOR
Intervention: Antisaccade task performance in healthy controls
Number of subjects: 35
Study 17656071 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline antisaccade error rate in UHR patients who transitioned to psychosis
Number of subjects: 35
Study 17656071 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial working memory function in UHR patients
Number of subjects: 35
Study 15449974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 50693
Study 15449974 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 50693
Study 11264688 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Chinese individuals
Number of subjects: 2096
Study 11264688 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 2096
Study 8988907 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn as zinc methionine
Number of subjects: 219
Study 8988907 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn + 20 mg Fe
Number of subjects: 219
Study 8988907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 8506732 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (5 x 2 Gy)
Number of subjects: 60
Study 8506732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiotherapy (10 x 2 Gy or 5 x 3.5 Gy)
Number of subjects: 60
Study 8506732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 60
Study 8506732 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vs High-dose radiotherapy
Number of subjects: 60
Study 3651109 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein 100 K.U. t.i.d. for 120 days
Number of subjects: 16
Study 3651109 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 100 mg t.i.d. for 120 days
Number of subjects: 16
Study 29984567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) based on NeckPix©, 4 sessions, 1-week duration
Number of subjects: 30
Study 29984567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) based on Tampa Scale of Kinesiophobia (TSK), 4 sessions, 1-week duration
Number of subjects: 30
Study 29984567 — intervention group
Group type: COMPARATOR
Intervention: Motor training (10 sessions, 5-week duration)
Number of subjects: 30
Study 28937784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacertus fibrosus
Number of subjects: 10
Study 28937784 — intervention group
Group type: COMPARATOR
Intervention: Achilles tendon
Number of subjects: 10
Study 26775476 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined EA anesthesia group (Group B)
Number of subjects: 54
Study 26775476 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia group (Group A)
Number of subjects: 54
Study 26775476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 24119994 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITN)
Number of subjects: 916
Study 24119994 — intervention group
Group type: COMPARATOR
Intervention: Anopheles mosquito biting behavior
Number of subjects: 916
Study 24119994 — intervention group
Group type: COMPARATOR
Intervention: Anopheles annularis
Number of subjects: 916
Study 21398582 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0
Study 21398582 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro manipulation of Programmed Death‐1 and 2B4 pathways
Number of subjects: 0
Study 18314433 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20‐40 mg)
Number of subjects: 334
Study 18314433 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to venlafaxine (150‐225 mg)
Number of subjects: 334
Study 18314433 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to a different SSRI plus cognitive behavioral therapy
Number of subjects: 334
Study 18314433 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to venlafaxine plus cognitive behavioral therapy
Number of subjects: 334
Study 18314433 — intervention group
Group type: COMPARATOR
Intervention: Medication switch alone
Number of subjects: 334
Study 15864239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 47
Study 15864239 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy volunteers)
Number of subjects: 47
Study 12202662 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300 mg/m²/d) and LV (90 mg/d) for 28 days every 35 days
Number of subjects: 380
Study 12202662 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (425 mg/m²/d) and LV (20 mg/m²/d) IV for 5 days every 35 days
Number of subjects: 380
Study 12202662 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 380
Study 12202662 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 380
Study 12202662 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV and 5-FU/LV
Number of subjects: 380
Study 10599909 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling plus systemic metronidazole and amoxicillin and supragingival irrigation with chlorhexidine digluconate
Number of subjects: 48
Study 10599909 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth scaling alone (control)
Number of subjects: 48
Study 7495241 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and multimineral supplements
Number of subjects: 3000
Study 7495241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 1683819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide, 70%
Number of subjects: 56
Study 1683819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrous oxide)
Number of subjects: 56
Study 6130074 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 12
Study 6130074 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 12
Study 6130074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1 g/kg) with Buspirone
Number of subjects: 12
Study 6130074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 12
Study 6130074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam with Alcohol
Number of subjects: 12
Study 30995972 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0·75 mg orally daily
Number of subjects: 2648
Study 30995972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2648
Study 30768615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) mass drug administration (MDA)
Number of subjects: 8445
Study 30768615 — intervention group
Group type: COMPARATOR
Intervention: Control villages (no early MDA)
Number of subjects: 8445
Study 28103942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner topical solution
Number of subjects: 224
Study 28103942 — intervention group
Group type: COMPARATOR
Intervention: Fipronil/(S)-methoprene combination
Number of subjects: 224
Study 25795029 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 52
Study 23173698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in twice-daily interferon-β/ribavirin therapy (IFN-β)
Number of subjects: 46
Study 23173698 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN/ribavirin therapy (PEG)
Number of subjects: 46
Study 21600384 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 244
Study 21600384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 19568011 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtX‐A) injection
Number of subjects: 52
Study 19568011 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline solution (placebo)
Number of subjects: 52
Study 16956684 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐36 Gy whole brain irradiation (WBI)
Number of subjects: 19
Study 16956684 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 19
Study 16956684 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and neurocognitive function data
Number of subjects: 19
Study 15059333 — intervention group
Group type: EXPERIMENTAL
Intervention: S + R (surgery plus radiotherapy)
Number of subjects: 495
Study 15059333 — intervention group
Group type: COMPARATOR
Intervention: S (surgery alone)
Number of subjects: 495
Study 11711490 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (estradiol valerate 1 mg daily; n=7)
Number of subjects: 12
Study 11711490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 12
Study 9158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training 3 days/week (ET3) for 6 months
Number of subjects: 67
Study 9158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training 5 days/week (ET5) for 6 months
Number of subjects: 67
Study 9158556 — intervention group
Group type: COMPARATOR
Intervention: Stretching/flexibility (SF3) for 6 months
Number of subjects: 67
Study 8427243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 61
Study 8427243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 2889654 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% Ophthalmic Solution
Number of subjects: 10
Study 2889654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31721425 — intervention group
Group type: EXPERIMENTAL
Intervention: MINDBODYSTRONG program (cognitive behavioral skill-building program)
Number of subjects: 89
Study 31721425 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (debriefing sessions)
Number of subjects: 89
Study 31721425 — intervention group
Group type: EXPERIMENTAL
Intervention: MINDBODYSTRONG program
Number of subjects: 89
Study 28746977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil/folinic acid (FUFA) chemotherapy
Number of subjects: 3239
Study 28746977 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3239
Study 28746977 — intervention group
Group type: EXPERIMENTAL
Intervention: High stromal proportion (≥65%)
Number of subjects: 3239
Study 28746977 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutation with high stromal proportion
Number of subjects: 3239
Study 27388615 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 100 mg once daily
Number of subjects: 81
Study 27388615 — intervention group
Group type: EXPERIMENTAL
Intervention: spironolactone 25 mg once daily
Number of subjects: 81
Study 27388615 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study 24402842 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative synbiotics
Number of subjects: 42
Study 24402842 — intervention group
Group type: COMPARATOR
Intervention: No synbiotics (control group)
Number of subjects: 42
Study 23640393 — intervention group
Group type: EXPERIMENTAL
Intervention: BOMP (bleomycin 7 mg days 1‐5, vincristine 0.7 mg m(‐2) day 5, mitomycin 7 mg m(‐2) day 5, cisplatin 14 mg m(‐2) days 1‐5, every 3 weeks for 2 to 4 cycles) plus RS (NACT group)
Number of subjects: 134
Study 23640393 — intervention group
Group type: COMPARATOR
Intervention: RS alone (RS group)
Number of subjects: 134
Study 23640393 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT group
Number of subjects: 134
Study 20689583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PQP); adults: 40 mg/320 mg; children: 20 mg/160 mg; n = 769
Number of subjects: 1150
Study 20689583 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine (AS+MQ); AS: 50 mg, MQ: 250 mg; n = 381
Number of subjects: 1150
Study 20689583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PQP)
Number of subjects: 1150
Study 20689583 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine (AS+MQ)
Number of subjects: 1150
Study 18254893 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP (8 pmol kg(‐1) min(‐1))
Number of subjects: 12
Study 18254893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16356539 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD40L in PAD patients with lengths >5 cm (N=38)
Number of subjects: 63
Study 16356539 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD40L in PAD patients with lengths < or = 5 cm (N=25)
Number of subjects: 63
Study 16356539 — intervention group
Group type: COMPARATOR
Intervention: sCD40L in control subjects (N=30)
Number of subjects: 63
Study 16356539 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1 in PAD patients with lengths >5 cm (N=38)
Number of subjects: 63
Study 16356539 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1 in PAD patients with lengths < or = 5 cm (N=25)
Number of subjects: 63
Study 16356539 — intervention group
Group type: COMPARATOR
Intervention: MCP-1 in control subjects (N=30)
Number of subjects: 63
Study 16356539 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP in PAD patients with lengths >5 cm (N=38)
Number of subjects: 63
Study 16356539 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP in PAD patients with lengths < or = 5 cm (N=25)
Number of subjects: 63
Study 16356539 — intervention group
Group type: COMPARATOR
Intervention: hs-CRP in control subjects (N=30)
Number of subjects: 63